Prime Medicine annual ebitda
2020
2021
2022
2023
2024
2025
Prime Medicine EBITDA Growth & History (PRME)
Prime Medicine's calculated EBITDA was −$201.0M for fiscal 2025.
View full Prime Medicine company overviewPrime Medicine annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$201.0M | −$4.7M | — |
| 2024 | 2024-12-31 | −$196.3M | $3.8M | — |
| 2023 | 2023-12-31 | −$200.1M | −$85.8M | — |
| 2022 | 2022-12-31 | −$114.3M | −$30.4M | — |
| 2021 | 2021-12-31 | −$83.9M | −$83.0M | — |
| 2020 | 2020-12-31 | −$889,000 | — | — |
Prime Medicine quarterly ebitda
Q3.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$41.5M | $10.0M | — |
| Q1 2026 | 2026-03-31 | −$48.8M | $1.9M | — |
| Q4 2025 | 2025-12-31 | −$46.7M | −$4.2M | — |
| Q3 2025 | 2025-09-30 | −$52.1M | $582,000 | — |
| Q2 2025 | 2025-06-30 | −$51.5M | $2.6M | — |
| Q1 2025 | 2025-03-31 | −$50.7M | −$3.7M | — |
| Q4 2024 | 2024-12-31 | −$42.5M | $24.3M | — |
| Q3 2024 | 2024-09-30 | −$52.7M | −$2.5M | — |
| Q2 2024 | 2024-06-30 | −$54.1M | −$10.0M | — |
| Q1 2024 | 2024-03-31 | −$47.0M | −$8.0M | — |
| Q4 2023 | 2023-12-31 | −$66.8M | −$29.0M | — |
| Q3 2023 | 2023-09-30 | −$50.2M | −$19.2M | — |
| Q2 2023 | 2023-06-30 | −$44.1M | −$18.3M | — |
| Q1 2023 | 2023-03-31 | −$39.0M | −$19.4M | — |
| Q4 2022 | 2022-12-31 | −$37.8M | — | — |
| Q3 2022 | 2022-09-30 | −$31.0M | −$20.8M | — |
| Q2 2022 | 2022-06-30 | −$25.9M | — | — |
| Q1 2022 | 2022-03-31 | −$19.6M | — | — |
| Q3 2021 | 2021-09-30 | −$10.2M | — | — |
Prime Medicine ebitda trends
Over the last five fiscal years, Prime Medicine's ebitda decreased from −$889,000 to −$201.0M, a change of −$200.1M. The latest reported quarter, Q2 2026, shows −$41.5M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Prime Medicine source filings ↗Community posts
Prime Medicine receives FDA clearance to test PM647 in humans
Prime Medicine ($PRME) received FDA clearance for its investigational new drug application for PM647, a prime-editing candidate for alpha-1 antitrypsin deficiency. The decision allows a first-in-human Phase 1/2 study of a single intravenous ...
